Article
Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host
2024-05-06
Abstract excerpt
<h4>Summary</h4> Glioblastoma (GBM) is the most common primary brain tumor in adults with a poor prognosis despite aggressive therapy. A recent, retrospective clinical study found that administering Temozolomide in the morning increased patient overall survival by 6 months compared to evening. Here, we tested the hypothesis that daily host signaling regulates tumor growth and synchronizes circadian rhythms in GBM...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7b158e8a-8431-5f3a-ba63-acdc65faa740
- DOI
- 10.1101/2024.05.03.592418
